Gadoteridol

prohance · ICG-Maleimide · Gadolinol · ICG-Hydrazide · 0))- · ICG HZ · SQ 32692 · gadotridol

https://huagongshe.com/de/chemical/60714

Identifikatoren & physikalische Daten

CAS No.	120066-54-8
Summenformel	C17H29GdN4O7
Durchschnittliche Molmasse	558,7 g/mol
Monoisotopische Masse	559,12774 g/mol
SMILES	CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3]
InChIKey	DPNNNPAKRZOSMO-UHFFFAOYSA-K
PubChem CID	60714

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	154
H-Brücken-Donoren	1
H-Brücken-Akzeptoren	11
Frei drehbare Bindungen	5
Schwere Atome	29
Formalladung	0
Komplexität	471
LogP (Verteilungskoeffizient)	log Kow = -3.68 (octanol/water)logP = -1.98 (butanol/water), at pH 7
Dichte	Osmolality (37 °C): 630 mOsM/kg waterviscosity (cP): 2.0 (20 °C), 1.3 (37 °C)density at 25 °C 1.140. /Gadoteridol injection/
Color/Form	White solid obtained as an aggregate clump of fine needle-like micro-crystals from methanol/acetone
Löslichkeit	In water, 737 mg/mLSolubility (mg/mL): methanol 119, isopropanol 41, dimethylformamide 10.1, acetonitrile 6.1, methylene chloride 5.2, ethyl acetate 0.5, acetone 0.4, hexane 0.2, toluene 0.3PBS (pH 7.2): 10 mg/ml
Schmelzpunkt	>225 °C188-193 °C
Other Experimental Properties	Hydrophilic
Lagerbedingungen	Store at -20°C
Aggregatzustand	A solid
Farbe	White to off-white
Hauptanwendungen	pharmaceutical (small molecule)
InChI	InChI=1S/C17H31N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26/h14H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28)/q-1+4/p-3
InChIKey	JOJFJDKAWWEUPD-UHFFFAOYSA-K
SMILES	CC1CN23CCN45CCN67CCN8(CC2)CC(=O)[O-][Gd+3]3486([O-]C(=O)C5)([O-]C(=O)C7)O1

Sicherheit & Vorschriften

FDA-Anforderungen	The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including gadoteridol, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
Lagerbedingungen	ProHance (Gadoteridol) Injection should be stored at 25 °C (77 °F) excursions permitted to 15-30 °C (59- 86 °F). Protect from light. Do not freeze.
Entsorgungsverfahren	SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Umweltverhalten	TERRESTRIAL FATE: The elements of the lanthanide series typically occur as the +3 ion either in solution or in compounds(1). Based on the Gd3+/Gd reduction potential of -2.28 V(1), gadolinium(III) ions do not undergo oxidation-reduction reactions under normal environmental conditions(SRC). Gadolinium ions are likely to adsorb to soils(SRC). In general, metal cations in solution are attracted to the negatively charged surfaces of soil particles(2). The extent of adsorption of metal ions to soils depends on the pH, the mineral content, and organic content of the soil(2). Gadolinium compounds do not volatilize from dry or moist soil surfaces due to their ionic character(SRC).
Toxizitätsübersicht	IDENTIFICATION AND USE: Gadoteridol is used as injectable contrast medium for Magnetic Resonance Imaging (MRI). HUMAN EXPOSURE AND TOXICITY: Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease , or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (older than 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic respiratory disorders. The literature describe a case of vasovagal response and anaphylactoid reaction during iv administration of gadoteridol. In an in vitro test, gadoteridol did not demonstrate any potential to hemolyze human erythrocytes when incubated in high concentrations with whole blood, suggesting there is little probability gadoteridol will cause hemolysis in vivo. ANIMAL STUDIES: Gadopentetate dimeglumine (Magnevist), gadoteridol (ProHance), gadodiamide (Omniscan), and gadoversetamide (Optimark) were evaluated at standard concentration and compared wi

Anwendungen & Verwendung

Verwenden

Gadoteridol is used as an MRI contrast chelating agent.